You are here

Cancer Immunotherapy, Part 2: Efficacy, Safety, and Other Clinical Considerations

C. Lee Ventola MS


The understanding of the relationship between cancer and the immune system has progressed rapidly in recent decades.13 The efficacy of many cancer immunotherapies, such as monoclonal antibodies, cytokines, cancer vaccines, and cell-based therapies, has been demonstrated, allowing these treatments to be incorporated into clinical practice.1,38 However, in some cancers and some patients, the success of cancer immunotherapy agents that target single molecular abnormalities or cancer survival mechanisms has been limited to clinical responses and modestly better survival.1,2 To improve outcomes, combination treatments with cancer immunotherapy agents may be necessary.13,6,9,10 This article provides an overview of the efficacy and safety of cancer immunotherapies, including additional clinical considerations regarding immune checkpoint blockers (ICBs).3,1117


In the past few decades, knowledge about the relationship between cancer and the immune system has grown quickly.1 The efficacy of many cancer immunotherapies has been demonstrated, causing the rapid integration of these treatments into clinical practice.1,3 One of the most attractive features of many cancer immunotherapies is that they target malignant cells while sparing normal, healthy tissues from the damage often seen with radiation and chemotherapy that contributes to patient morbidity and mortality.3

Previously, cancer immunotherapies had been associated with only a few examples of predictable clinical success, such as the use of high-dose interleukin (IL)-2 to achieve a complete response (CR) in advanced melanoma and renal cell carcinoma (RCC).1 However, further progress has since been made, and cancer immunotherapy is now more often considered to be effective (Table 1).1,3 Positive responses with cancer immunotherapy are reported more frequently—sometimes even complete or long-lasting responses or cures, even in patients with solid tumors or aggressive malignancies.13 At present, cancer immunotherapy has been shown to be most beneficial in treating patients with melanoma, RCC, or hematologic malignancies.3 However, emerging data are demonstrating the potentially broader efficacy of immunotherapy in treating many other types of malignancies.3

Among the considerations when selecting a cancer immunotherapy to treat a patient are the treatment goals, patient’s status, type of tumor, speed of disease progression, and potential efficacy and adverse effects (AEs).3 Because patients with cancer often have a limited therapeutic window, the extended time needed to generate certain immunotherapies is another consideration that could eliminate some treatment choices.3 For example, genetically engineered cytotoxic T lymphocytes (CTLs) can take weeks to months to prepare.3,18 AEs associated with cancer immunotherapies can be mild and localized or more severe and systemic, depending on the treatment.3

In general, the AEs that may develop with cancer immunotherapy depend on the treatment modality, route of administration, and mechanism of action.3 Some immunotherapies broadly activate the immune system, while others precisely target distinct tumor antigens.3 Vaccines that are administered locally may have a potent effect in stimulating an immune response at the injection site, while the AEs observed with cytokines and ICBs (both which induce the broad activation of the immune system) can produce symptoms that are often observed during high levels of immune activity, such as those accompanying a systemic infection.3 Another important consideration with respect to some cancer immunotherapies is the possibility of long-term antitumor effects due to “immune memory.” 3,19,20 Although this effect can be beneficial, it can also be a double-edged sword because it can lead to long-lasting toxicities, such as those seen with allogeneic hematopoietic stem cell transplant (allo-HSCT), which can potentially cause a broad, prolonged immune response against normal tissue.3

A brief overview of the efficacy and safety of various cancer immunotherapy agents follows.


The ability to identify and characterize proteins associated with tumors has led to the development of targeted therapies, such as therapeutic monoclonal antibodies (mAbs).10 In 1997, the first therapeutic mAb demonstrated sufficient efficacy to receive approval from the Food and Drug Administration (FDA), and rituximab (Rituxan, Genentech/Biogen Idec) was approved for the treatment of relapsed or refractory CD20+, B-cell, low-grade or follicular non-Hodgkin’s lymphoma.5,8 Since then, many other therapeutic mAbs have been granted FDA approval for use in a wide range of clinical indications, including: cetuximab (Erbitux, Eli Lilly) for head and neck cancer and colorectal cancer (CRC); trastuzumab (Herceptin, Genentech) for human epidermal growth factor receptor 2 (HER-2)-positive breast cancer and gastric and gastroesophageal cancer; ofatumumab (Arzerra, Novartis) for chronic lymphocytic leukemia (CLL); alemtuzumab (Campath, Genzyme) for B-cell CLL; panitumumab (Vectibix, Amgen) for CRC; and bevacizumab (Avastin, Genentech) for CRC, nonsquamous non–small-cell lung cancer (NSCLC), glioblastoma, RCC, cervical cancer, and recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.4,5,7 Over the past 20 years, therapeutic mAbs have become mainstays of cancer treatment for a variety of malignancies, including breast cancer, lymphoma, and CRC. Notably, rituximab and trastuzumab have demonstrated such significant utility in treating lymphomas and HER-2/neu-positive breast cancer, respectively, that they have become important components of curative regimens for these malignancies.1

Because they are targeted, the side effects that occur with therapeutic mAb treatment are generally considered to be mild compared with other types of cancer treatment.4,14,15 Side effects that can occur with mAbs include chills, diarrhea, fever, headache, low blood pressure, nausea, rashes, weakness, and vomiting.15 Toxicity associated with a therapeutic mAb may also relate to its specific pharmacological activity.14 Although targeted, therapeutic mAbs may also cause toxicity by interacting with the target antigen where it is present in places other than the intended tissue.14 For example, the skin toxicity observed with cetuximab (approved for head and neck cancer) is believed to occur because the target antigen, epidermal growth factor receptor (most often known simply as EGFR), is also present on human keratinocytes.14 Although many AEs seen with mAbs are antigen-/target-related, off-target, nonspecific toxicity can also be observed; for example, hypersensitivity reactions are common and are thought to be related to the immunogenicity of mAbs.14 Fully human mAbs generally have reduced immunogenicity compared with chimeric or humanized mAbs.14 This is because mAbs composed of a high proportion of nonhuman sequences are more likely to be identified as “foreign,” thereby inducing a host immune response.14 This can result in reduced efficacy and more AEs, due to greater clearance and an increase in infusion- or injection-site reactions.14

Although the use of “naked” (unconjugated) therapeutic mAbs (those that work by themselves) has significantly impacted cancer treatment, efficacy can often be improved by linking them to a biologically active cytotoxic drug or a radioisotope (radioimmunoconjugate).8,10 Brentuximab vedotin (Adcetris, Seattle Genetics), for example, is an antibody–drug conjugate that was generated by conjugating a humanized anti-CD30 mAb, SGN-30, to the cytotoxic agent monomethyl auristatin E. It is approved for the treatment of classical Hodgkin’s lymphoma and systemic anaplastic large cell lymphoma.8 Another antibody–drug conjugate, ado-trastuzumab emtansine (Kadcyla, Genentech), which is conjugated to the maytansinoid DM1, a cytotoxic agent, has been approved for the treatment of HER-2-positive metastatic breast cancer.8 An example of a mAb that is conjugated to a radioisotope is ibritumomab tiuxetan (Zevalin, Spectrum Pharmaceuticals), which has demonstrated encouraging results in treating patients with non-Hodgkin’s lymphoma.8 It should be noted that while conjugated antibodies can be more effective than “naked” mAbs, they can also cause more side effects, depending on the substance attached to them.15

Because of the heterogeneity of tumors, it has been recognized that for treatment to succeed, it may be necessary to employ a combination of targeted therapies.10 Therefore, during the past few years, attention has turned to developing mAbs that target a variety of tumor-associated antigens, such as surface glycoproteins.10 More information regarding FDA-approved therapeutic and ICB mAbs is presented in Table 2. Numerous new mAbs are in phase 3 clinical trials or are already being reviewed by regulatory authorities.5

Immune Checkpoint Blockers

ICBs are a type of mAb that have rapidly emerged as a promising cancer immunotherapy.3 They are becoming more broadly used, particularly in advanced cancer when standard chemotherapy has not been effective or is not a promising treatment option.7 Currently approved ICBs block immune checkpoints such as the cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) receptor or the interaction between programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1).6 Among others, the ICBs approved by the FDA have included ipilimumab (Yervoy, Bristol-Myers Squibb), nivolumab (Opdivo, Bristol-Myers Squibb), and pembrolizumab (Keytruda, Merck Sharp & Dohme Corp.), each for different indications such as melanoma, RCC, NSCLC, Hodgkin’s lymphoma, head and neck squamous cell carcinoma (HNSCC), and urothelial carcinoma.2,6,9

Evidence for clinical response with ICBs is accumulating in many different types of cancer, so treatment indications for these agents are expected to expand.6 Indeed, clinical trial data have shown that approximately 15% to 25% of patients (and sometimes more) with various types of cancer respond to ICBs.7,16 Positive objective response rates (ORR) following ICB treatment have been reported in many malignancies, including gastric cancer (20%), HNSCC (12% to 25%), hepatocellular carcinoma (20%), ovarian cancer (15%), small-cell lung cancer (15%), triple-negative breast cancer (20%), urothelial cancer (25%), mismatch repair-deficient CRC (60%), and Hodgkin’s lymphoma (65% to 85%).6 Patients with bladder cancer who have a high expression of PD-L1 have demonstrated ORRs as high as 40%.16

Currently, the response observed with ICBs is most often a partial response (PR), at rates comparable to other targeted agents or chemotherapy.16 However, the degree of response observed with ICBs can be extreme (i.e., 80% to 90% tumor shrinkage), as well as durable.7,16 Until recently, surgeons were reluctant to operate on a patient with advanced metastatic cancer because doing so was unlikely to lengthen the patient’s life.7 However, in some of these patients, ICBs have been able to eliminate or shrink the tumors to sizes and locations where they can be surgically removed.7 Furthermore, even a PR to ICB treatment can be durable compared with that seen with chemotherapy or other targeted therapies.16 In some cases the prolonged benefit that has been observed with ICB treatment can be considered a functional cure.16 It is important to note, however, that because CTLA-4 agents work by stimulating anticancer T cells in circulation, months may be required to activate enough T cells to elicit a response.7,16 In contrast, with anti-PD-1/PD-L1 therapies, a more rapid response is often observed because these drugs act on primed T cells that are already located in the tumor.16 Still, for most types of cancer, only a minority of patients respond to currently available ICBs, so research is focused on developing others that target additional immune checkpoints that may be present in these cancers, as well as identifying combination therapies that use several targeted agents.16

Because ICBs enhance the immune response against cancer cells, they can also cause inflammatory side effects known as immune-related adverse events (irAEs).6,12 Such toxicities are distinct from those caused by traditional chemotherapy or other molecularly targeted therapies.6 The irAEs associated with ICBs are caused by the infiltration of normal tissues with activated T cells that are also involved in autoimmunity.6 Because immune checkpoints play a key physiological role in the body, they are also expressed by normal tissue, so blocking them with ICBs can cause a widespread immune response that can affect even the body’s organs.6

The spectrum of toxicities observed with the currently used anti-CTLA-4 and anti-PD-1/PD-L1 ICB agents are similar, but the frequency of occurrence differs.6 For anti-CTLA-4 agents, the toxicities observed in more than 10% of patients have been anorexia, abdominal pain, diarrhea, fatigue, nausea, pruritus, rash, and vomiting.6 With anti-PD-1/PD-L1 agents, the toxicities observed in more than 10% of patients have been arthralgia, diarrhea, fatigue, nausea, pruritus, and rash.6 In addition, the AE profile for anti-PD-1/PD-L1 agents is considered to be milder than that of anti-CTLA-4 ICBs; the rate of grade 3 or 4 toxicities with anti-CTLA-4 agents has been observed to be 20% to 30% versus 10% to 15% for anti-PD-1 agents.6,16 Importantly, although severe irAEs occur in a small minority of patients receiving ICB treatment, they can become life-threatening if not anticipated and appropriately managed.6 The main life-threatening toxicities with anti-CTLA-4 treatment and PD-1/PD-L1 agents are dysimmune colitis and interstitial pneumonitis, respectively.6 However, other severe toxicities associated with ICB treatment have been reported, including autoimmune anemia, infusion reactions, type-1 diabetes with ketoacidosis, Guillain–Barré syndrome, Stevens–Johnson syndrome, and thrombocytopenia with bleeding complications.6

Figure 1 provides a representation of the types of AEs that have been reported with ICBs.6



In 1996, interferon (IFN)-α2b was approved by the FDA for the treatment of advanced melanoma.3,5 Since then, IFN-α2b has become the standard treatment for patients with stage III (resected node-positive) melanoma, and it is also strongly considered for patients with high-risk stage IIB or IIC melanoma.3,5 The ORR for IFN-α2b in patients with advanced melanoma has been reported as 22%; however, response has been limited to patients with a small disease burden.21

Once IFN-α2b was observed to have antitumor activity against metastatic melanoma (MM), the Eastern Cooperative Oncology Group conducted a study in stage II and III high-risk melanoma patients who were assigned to receive either a year-long treatment of high-dose IFN-α2b or standard chemotherapy.22 This study showed that high-dose IFN-α2b increased median relapse-free survival by nine months and overall survival (OS) by one year, and had also improved both of these measures by nearly 10% at five years.22 This study also found that IFN-α2b treatment improved patient quality of life and was cost-effective.22 Studies that have investigated the timing and dosing of IFN-α2b as an adjuvant therapy for advanced melanoma have not agreed on the best method of administration.3

IFN-α has also been used to treat patients with RCC or hematologic malignancies.3,5 The use of IFN-α for the treatment of patients with RCC has demonstrated small benefits, improving survival by about four months.23 However, this use has decreased due to the availability of therapeutic mAbs, such as axitinib (Inlyta, Pfizer), sorafenib (Nexavar, Bayer HealthCare Pharmaceuticals), and sunitinib (Sutent, Pfizer) and the ICB nivolumab for the treatment of RCC, which do not have the toxicities associated with IFN-α treatment.3 In hematologic malignancies, IFN-α2b has also been used to treat hairy cell leukemia with some success, but other agents are preferred for the treatment of this disease.3,5

The most common AEs observed with IFN-α treatment are flu-like symptoms, including chills, fever, headache, and myalgias.22 These effects may be severe and have been associated with the withdrawal of a significant proportion of patients enrolled in IFN-α trials.3 Additional toxicities associated with IFN-α treatment include anorexia, depression, hepatic dysfunction, and thyroid abnormalities.3 However, these effects usually reverse rapidly upon treatment cessation.24


High-dose recombinant IL-2 (rhIL-2) was first approved for the treatment of metastatic RCC by the FDA in 1992 and then received approval for MM in 1998.1,3,5 For RCC, a high-dose of rhIL-2 (600,000–720,000 IU/kg) is administered as an intravenous bolus over consecutive days.3 This regimen is repeated for several cycles depending on tumor response.3 A similar treatment regimen of high-dose rhIL-2 therapy is followed for the treatment of MM.1,3

A longitudinal study spanning 20 years showed that high-dose intravenous rhIL-2 treatment of RCC produced an ORR of 20% and a CR in 8.9% of patients.25 During follow-up visits ranging from 24 to 221 months after therapy, 83% of the patients in CR remained recurrence free at last follow-up visit.25 In MM, high-dose intravenous rhIL-2 treatment is expected to achieve lower ORR and CR, which were observed in 16% and 6% of patients, respectively.26 Nonetheless, because durable responses have been observed in patients with MM who had achieved a CR following rhIL-2 treatment, this treatment is considered a valid option for these patients.3

AEs observed with rhIL-2 treatment include anemia, cardiac arrhythmia, chills, confusion, diarrhea, eosinophilia, fever, hypotension, lethargy, metabolic acidosis, nausea, thrombocytopenia, and organ failure (including hepatic and renal failure).3,27 Because of potential organ toxicity, patients who are expected to be treated with rhIL-2 are routinely screened for organ function prior to its use, and extra caution is taken when patients with organ failure are treated.27,28 Even in patients who have normal organ function, toxicities can occur with high-dose rhIL-2 therapy that require treatment cessation to allow the patient to recover.3 Fortunately, although they can be severe, most AEs occurring with high-dose rhIL-2 treatment tend to be rapidly reversible.3

This therapy may also cause a severe, potentially life-threatening reaction due to the stimulation of proinflammatory cytokines, leading to vasopermeability, vascular leak, and a sepsis-like syndrome.3 Because of the potential for these severe toxicities, administration of rhIL-2 is often restricted to treatment centers with established protocols and experienced clinicians.3 In some institutions, rhIL-2 is administered only in the intensive care setting.3

Because of the severe toxicity seen with rhIL-2 treatment, studies were conducted to determine the efficacy of alternative dosing regimens.3 These studies involved a change in the route of administration and dose, or the administration of rhIL-2 with other treatments.3 In a phase 3 study by the National Cancer Institute, standard high-dose rhIL-2 treatment was compared to low-dose treatment (72,000 IU/kg) in the treatment of RCC.29 High-dose rhIL-2 achieved a response rate of 21%, compared with 13% for low-dose treatment (P = 0.048).29 In addition, the duration of response and survival in patients who had achieved a CR was determined to be higher in those who had received a high dose rather than a low dose (P = 0.04).29 As expected, a higher incidence of AEs was seen in the high-dose group, but there was no difference in the incidence of death attributable to rhIL-2 treatment between the two groups.29


Cancer vaccines have been studied in a wide variety of tumor types, but to date they have yielded mostly discouraging results.2,4 The overall outcomes of treating established tumors with vaccines have been suboptimal, with clinical benefit in the majority of patients being prolonged survival rather than remission.5,11 However, one vaccine, sipuleucel-T (Provenge, Dendreon), has been approved for the treatment of men with prostate cancer.1

Preclinical models have demonstrated that once tolerance is established in poorly immunogenic tumors, treatment with vaccines alone is ineffective at reducing a significantly established tumor burden.11 Only a limited activation and expansion of tumor-specific T cells occurs in response to treatment with a vaccine, which is likely a consequence of: 1) tumor-mediated immune suppression; 2) low affinity of autologous T cells to self-antigens; and 3) patient immune system suppression due to other treatments, such as systemic chemotherapy administration.5,11 Although many newer-generation vaccines can activate dendritic cells, T-cell tolerance remains a barrier that is difficult to overcome by vaccination alone.9 Some researchers have suggested that the inability of cancer vaccine treatment to induce a remission is due to “suboptimal design.” 11 They suggest that better results may be obtained with improvement in the choice of antigen, and with combination therapy using other agents (such as ICBs) that reverse immunosuppressive mechanisms.11

Polyvalent cell-based cancer vaccines (such as dendritic-cell or tumor-cell vaccines) can include a wide range of tumor-associated antigens and are considered promising; however, technical difficulties impede their clinical use.2 With respect to antigen choices, neoantigens that appear as a result of tumor-specific mutations have been considered particularly relevant to therapeutic cancer vaccination because T cells for these antigens are not deleted by central tolerance mechanisms, which renders them inactive.11 However, the process of identifying tumor neoantigens is labor intensive and time consuming, so few have been found.3 This is a major limitation for this technique because most known tumor antigens are tumor-associated and not tumor-specific.3,11 Although these antigens are broadly expressed by malignant cells, they are also expressed by normal tissues, so cancer treatments targeting tumor-associated antigens can potentially cause irAEs.3 Therefore, the ideal goal of therapeutic vaccination is to induce an immune response that targets antigens that are only expressed by cancer cells.3

Peptide-Based Vaccines

Peptide-based vaccines have two major limitations in cancer treatment.3 First, knowledge of the immunogenic tumor-specific proteins, their presence in different tumors, and identification of the peptide sequence within these proteins that elicit the immune response is necessary.3 Second, because these peptide-based vaccines are human leukocyte antigen (HLA)-restricted, prior knowledge of the patient’s HLA type is also required.3 Most tumor antigens are proteins that are structurally homologous among different individuals; however, small nine- to 14-amino-acid peptides are expressed on the tumor cell surface in association with HLA molecules that must also be identified.3 Despite these limitations, initial clinical studies have shown that peptide vaccines can stimulate antigen-specific immune responses and have highly favorable toxicity profiles, so there is interest in further investigating these agents.3

The use of peptide vaccines targeting three well-characterized melanoma antigens (MART-1, gp100, and tyrosinase) has been investigated.3 These antigens were targeted individually, as well as in a multi-epitope approach, in order to broaden the immune response elicited against melanoma.3 In a phase 3 clinical trial, 185 patients (identified as type HLA-A2+) with locally advanced stage III or IV cutaneous melanoma were randomly assigned to receive rhIL-2 alone or gp100 peptide vaccine followed by rhIL-2.20 The clinical response was found to be greater in the group who had also received the gp100 peptide vaccine, compared with those receiving rhIL-2 alone (16% versus 6%, respectively; P = 0.03).20 Patients who had received the vaccine also experienced significantly longer progression-free survival (2.2 months versus 1.6 months; P = 0.008), as well as longer OS (17.8 months versus 11.1 months; P = 0.06).20 The AEs experienced by patients in this study were determined to result primarily from rhIL-2.20

Peptide vaccines have also been investigated in clinical trials involving patients with breast cancer.3 The most studied immunogenic peptide that has been observed in breast cancer is E75, which is an HLA-A2/A3-restricted, nine-amino-acid peptide derived from the HER-2 protein.3 A phase 1/2 study investigated E75 given in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) in an adjuvant setting to prevent disease recurrence in high-risk node-negative and node-positive breast cancer patients.30 Administration of the E75 peptide vaccine resulted in increased disease-free survival of 94.3% in vaccinated patients, compared with 86.8% in control patients.30

In this trial, the E75 peptide vaccine was associated with only mild local and systemic toxicities.30 The local toxicities were judged to be grade 1 in 81% and grade 2 in 19% of patients, the most common being erythema or pruritus at the injection site.30 Systemic toxicities were judged as grade 0 in 12%, grade 1 in 71%, grade 2 in 14%, and grade 3 in 2% of patients.30 However, many observed toxicities were consistent with GM-CSF administration; therefore a 50% dose reduction in this agent was instituted for the 17.9% of patients who had experienced systemic toxicity higher than grade 2, or an inoculation site reaction that was greater than 100 mm in diameter.30 All patients requiring dose reductions had been assigned to the two highest-dose groups and experienced no recurrences.30

Peptide vaccines have also demonstrated efficacy in the treatment of hematologic malignancies.3 WT1 is a zinc finger transcription factor overexpressed in chronic myeloid leukemia, acute myeloid leukemia (AML), and solid tumors.3 Clinical studies have been conducted with three nonamer peptides derived from WT1: one that is HLA-A*0201 restricted and two that are HLAA*2402 restricted.3 In one study that enrolled patients with AML and HLA-A*0201, a CR in one patient and stable disease in 12 patients were observed after a treatment regimen of WT1 peptide vaccine combined with keyhole limpet hemocyanin and GM-CSF.31 Following vaccination, WT1 mRNA levels were measured, which detected an increase in the levels of blood and bone marrow WT1-tetramer + CTL, and a threefold decrease in disease burden in 35% of patients.31 AEs were limited to transient local erythema, fatigue (grade 1 or 2), fever (grade 1), and pruritus (grade 1 or 2).3 In addition, two patients with erythema nodosum-like lesions developed a grade 2 cough but did not have radiological abnormalities of the lungs.31

Immune or Dendritic Cell-Based Vaccines

In 2010, sipuleucel-T was the first cancer vaccine to obtain FDA approval for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.3,5,13 Sipuleucel-T is an autologous cell-based vaccine designed to use the patient’s own immune system to generate antitumor immunity to extend patient OS.3,5,13 To develop this vaccine, the patient must undergo leukapheresis to obtain peripheral blood containing antigen-presenting cells (APCs), including dendritic cells.3 The APCs are exposed to recombinant antigen PA2024 (which includes prostatic acid phosphatase [PAP], a protein expressed in approximately 95% of prostate cancers) and GM-CSF, which they take up, resulting in the generation of mature PAP-specific APCs that can activate patient T cells to target the PAP expressed on prostate cancer cells.3,5

The efficacy of sipuleucel-T was demonstrated in the double-blind, placebo-controlled IMPACT trial, which enrolled 512 patients.32 In this study, 341 patients who received sipuleucel-T had a median OS of 25.8 months, compared with 21.7 months for the 171 patients receiving placebo.32 Time to disease progression was similar in both groups (14.6 weeks versus 14.4 weeks).32 Endpoints used to measure immune response (T-cell levels and antibody titers) were higher in patients who received the vaccine, confirming immune-system stimulation.32 Despite modest efficacy, sipuleucel-T has a low toxicity profile, which may make it an attractive option for the treatment of patients with metastatic castration-resistant prostate cancer.3 The most commonly reported AEs, occurring in 10% to 50% of patients, included anemia, back pain, chills, fatigue, fever, headache, and nausea.32 These AEs usually resolve within one to two days after infusion.32 Less frequent side effects, observed in less than 10% of patients, included hematuria, cerebrovascular events, hypertension, hypokalemia, rash, and respiratory symptoms.32

Tumor Cell-Based Vaccines

The efficacy and safety of tumor cell-based vaccines have also been studied in the treatment of cancer. MVax (AVAX Technologies, Inc.), an investigational autologous tumor-cell vaccine, was developed using melanoma tumors.3 The treatment of melanoma with MVax was investigated in a phase 2 clinical trial that enrolled 97 patients.33 The results demonstrated an increase in median survival for patients whose tumors regressed after receiving the vaccine: 21.4 months versus 8.7 months for patients who had shown no improvement (P = 0.01).33 The major AE associated with MVax treatment was the appearance of pustules or papules with small ulcerations at the injection site, primarily due to the Bacillus Calmette–Guérin immuno-adjuvant component.33 These lesions healed within approximately three months, but small scars remained.3 In addition, fewer than 5% of patients reported fever or malaise during the 24 hours after vaccine administration.33

Work is also being conducted with tumor-cell vaccines that use the GVAX (Aduro Biotech) platform, which involves transducing tumor cells with GM-CSF prior to administering them as part of a vaccine to treat AML or solid malignancies.3,5 In a phase 2, open-label, single-arm trial that enrolled patients with AML, a tumor-cell–based vaccine developed using the GVAX platform was administered, followed by induction and consolidation chemotherapy and autologous stem cell transplantation.34 This study enrolled patients who were 18 to 60 years of age who had not previously received leukemia therapy.34 Treatment elicited antitumor T-cell and antibody responses, as well as a reduction in minimal residual disease in some patients.34 AEs were minimal, appearing as flu-like symptoms and injection-site reactions.34

Oncolytic Virus-Based Vaccines

Oncolytic viruses can selectively infect cancer cells to cause direct lysis, can disrupt the tumor vasculature, and can induce an antitumor immune response.35 The association between immune activation and oncolytic virus efficacy has led to interest in viruses that encode immunostimulatory agents.35 One such virus, talimogene laherparepvec (T-VEC), received FDA approval in 2015 as Imlygic (Amgen) for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in melanoma that recur after initial surgery.36 T-VEC is an intratumoral injection of herpes simplex virus type 1 genetically modified to produce GM-CSF in the tumor microenvironment, causing tumor lysis.36 In a phase 3 trial, 436 patients with advanced nonresectable melanoma received periodic intralesional injections of T-VEC or administration of GM-CSF.36 Patients receiving T-VEC had an improved durable response rate (a CR or PR maintained for at least six months), but no statistically significant improvement in OS compared with patients given GM-CSF.36


Autologous Cell Transfer

In the late 1980s and early 1990s, Rosenberg and colleagues first utilized tumor-infiltrating lymphocytes (TILs) concomitantly with rhIL-2 to treat MM patients.1,3,37 In a study enrolling 86 patients, 34% (n = 29) of those receiving this treatment exhibited a CR or PR; however, only five of these patients had achieved a CR.38 One of the major obstacles that was identified was the transient survival of the transferred cells.38 After one week, only 0.1% of the total cells in the body were found to be transferred cells, despite 80% of the patients having received more than 1011 cells.38 The transient survival of the TILs led to subsequent studies that investigated lymphodepleting chemotherapy combined with autologous cell transfer.39 These studies successfully demonstrated the persistent clonal repopulation of the infused TILs following lymphodepletion.39

After this technique was discovered, a study was conducted to better characterize the efficacy of various methods of lymphodepletion.40 This study evaluated two approaches—chemotherapy and total body irradiation (TBI).40 Ninety-three patients were enrolled; 43 received chemotherapy and 50 received TBI at a dose of 2 Gy (n = 25) or 12 Gy (n = 25).40 Both chemotherapy and TBI were administered in combination with rhIL-2 therapy.40 The study reported ORRs of 49%, 52%, and 72% for chemotherapy, 2 Gy TBI, and 12 Gy TBI, respectively.40 A follow-up study found that 22% of patients receiving treatment had achieved CR.19 Furthermore, the patients who had achieved CR had three- and five-year survival rates of 100% and 93%, respectively.19 The three- and five-year survival rates reported for the entire group were 36% and 29%, respectively.19 In these studies, the AEs associated with TIL treatment were minimal, with most attributed to rhIL-2 therapy and TBI.3 However, despite promising results, limitations remain regarding the use of TIL treatment.3 The time and cost required for TIL production is a major challenge.18 Obtaining a sufficient number of TILs is also difficult because of cell loss during TIL purification.3 Because of the limitations involved in generating autologous TILs, nonautologous approaches are being investigated.3,5

One of the most promising developments with respect to the use of autologous cell transfer to treat cancer has been the development of chimeric antigen receptors (CARs).3,5,11 In a seminal study, CAR-modified T cells successfully targeted the B-cell antigen CD19 in a patient with CLL.3 Evaluation of the patient’s bone marrow found no evidence of CLL 28 days after the initial CAR injection.3 There were also no acute AEs; the only significant toxicity was grade 3 tumor lysis, which had been expected due to a large disease burden.3 In another study, patients with B-cell acute lymphoblastic leukemia and CLL were treated with CAR-based immunotherapy treatments that targeted the surface antigen CD19.5 The CAR T cells that had been infused persisted for more than one year in some patients, and the antitumor effect was associated with depletion of B-lymphopoiesis.5 The most frequently occurring serious AE associated with CAR T-cell therapy was cytokine release syndrome (CRS).5 Other types of cancer, such as carcinomas or AML, have been treated with CAR T-cell–based therapy without significant success.5 Further studies are ongoing to determine the efficacy of CAR T cells in treating a number of malignancies.3,5

While toxicities related to CAR T-cell therapy are not fully understood, they may be so severe as to limit the use of this approach.41 CRS, marked by fever, hypotension, tachycardia, and other symptoms, has emerged as a prominent AE.41 A higher disease burden may predict more severe CRS, and patients with limited comorbidities may be better able to tolerate the surge of cytokines.41 After administration of CAR T-cell therapy, close hemodynamic monitoring is vital; hypotension must be managed aggressively.41 Tocilizumab and corticosteroids have been used to treat CRS-related AEs after CAR T-cell therapy.41

Allogeneic HSCT

Allo-HSCT plays a major role in the standard-of-care treatment of patients with AML, acute lymphoblastic leukemia, CLL, Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma.13 In AML patients who lack favorable prognosticators, allo-HSCT has been shown to provide an improvement in four-year OS (40% versus 30%) and disease-free survival (33% versus 17%) compared with patients who have received non-allo-HSCT-based therapies.4244 Allo-HSCT is also often used to treat patients with relapsed hematologic malignancies following achievement of a second remission or after the first CR if the cancer is associated with known high-risk prognostic markers, such as molecular and cytogenetic mutations.3 In relapsed or refractory AML, allo-HSCT has been shown to provide the greatest chance of a cure.3

Although allo-HSCT may be one of the most fundamental immunotherapeutic approaches, it is also one of the most toxic cancer treatments.3 Unlike the AEs that occur with cytokine therapy, which are reversible following cessation of treatment, AEs associated with allo-HSCT are long-lasting due to the memory effects associated with the infused donor graft.3 These toxicities can appear or continue years after allo-HSCT treatment because the infused donor immune cells are repeatedly primed by infectious exposures that can cause autoimmune responses against normal tissues.3 A major AE associated with allo-HSCT is graft-versus-host disease (GvHD), which is classified as either acute (aGvHD) or chronic (cGvHD).3 This classification was initially based on the time of onset after donor-cell infusion, with the 100th day acting as the cutoff for aGvHD.3 However, GvHD is now more accurately classified based on the type of symptoms and the tissue damage that occurs.45

GvHD occurs in almost 50% of patients receiving allo-HSCT, with cGvHD accounting for 22% of treatment-related patient mortality between the second and fifth year after treatment.46 The most common form of GvHD affects the skin, ranging in presentation from a localized, mild skin rash to extensive involvement that includes bullous lesions and sloughing.47,48 However, GvHD can also involve the upper gastrointestinal (GI) tract, manifesting with upper GI symptoms, including nausea and vomiting (which can cause severe anorexia), and/or lower GI symptoms, such as severe diarrhea.3 GvHD can also manifest with hepatic symptoms related to biliary obstruction, which can then progress to fulminant liver failure.47,48 The mainstay of GvHD treatment is immunosuppression, specifically corticosteroids.3 However, long-term corticosteroid treatment is associated with major side effects, including aseptic bone necrosis, adrenal insufficiency, cataract formation, diabetes mellitus, myopathy, opportunistic infections, and osteoporosis.3 In addition, 40% of patients with GvHD are refractory to corticosteroid treatment and have a poor prognosis for long-term survival (5% to 30%).49 Presently, there is no well-defined approach to treating patients with steroid-refractory GvHD (SR-GvHD); however, therapies that inactivate alloreactive donor T cells or proinflammatory cytokines or their receptors have been investigated.49 An analysis of 25 retrospective studies or phase 2 trials concluded that the weighted average six-month survival for patients with SR-GvHD treated with these therapies was 49%.49 Among the agents used were an anti-CD25 monoclonal antibody (basiliximab [Simulect, Novartis]), anti-tumor necrosis factor-alpha (infliximab [Remicade, Janssen] and etanercept [Enbrel, Amgen]), antithymocyte globulin, anti-IL-2α (inolimomab), anti-CD52 (alemtuzumab [Campath, Genzyme]), and pentostatin, among others.49


In some patients, treatment with a single cancer immunotherapy is sufficient to achieve a prolonged clinical benefit or even a cure.1 This is in accordance with the principles of natural selection, in that if a treatment impedes the chief mechanism by which a cancer has evolved to successfully escape the host immune system, monotherapy may be sufficient to reawaken the body’s anticancer immune response.1 To date, administering agents that target single cancer pathways or molecular abnormalities has achieved good clinical responses and modestly improved survival in some cancers.2 However, this reductionist approach to cancer treatment may be insufficient to overcome the challenges that prevent improved outcomes.2 In some cases, to achieve long-term efficacy, it may be necessary to use drug combinations that target several molecular alterations and other survival mechanisms that specific cancers have adopted.1,2 But for this approach to succeed, researchers must better understand the nascent resistance mechanisms that are clinically relevant to impeding effective immunotherapy.1 For these reasons, combination therapy could potentially be one of the most challenging but most promising cancer treatment strategies in the future.2

Many treatments that combine cancer immunotherapy agents together or with other types of drugs are currently being investigated or are expected to be in clinical trials within the next few years.1 Cancer immunotherapies will be investigated in combination with one another, chemotherapy, and radiation in an effort to block a broader spectrum of cancer-cell signaling and exploit cytoreductive strategies.1 The combination of PD-1 and CTLA-4 ICBs has already demonstrated efficacy in treating malignant melanoma.1 As new ICB agents that target additional checkpoints are developed, they will also likely be studied in combination treatments.1 Combination treatments of therapeutic vaccines administered together with ICBs and agonists for costimulatory pathways have also proven capable of generating significant antitumor responses, even in cases of established metastatic cancer.9 Other strategies that are being investigated include combining therapeutic vaccines with novel immune modulators or cytokines.3 The combination of gp100 peptide with rhIL-2 has been very effective in improving clinical outcomes in patients with melanoma; however, this approach has not yet become part of standard treatment.3 Combinations of ICBs with cellular therapies are also being investigated.1

Although combined immunotherapy treatment is a viable strategy for improving efficacy, increased toxicity has been reported when ICBs have been combined or administered with other targeted therapies or conventional chemotherapy.6 As noted earlier, the rate of grade 3 or 4 toxicities has been reported to be 20% to 30% for anti-CTLA-4 and 10% to 15% for anti-PD-1 ICBs.6 However, when ipilimumab and nivolumab were administered in combination, the rate of grade 3 or 4 toxicities was observed to be 55%.6 Similarly, in a study that investigated the combination of ipilimumab with conventional chemotherapy in lung cancer, the rate of grade 3 or 4 toxicities was found to be 58% (compared to 42% in the group receiving chemotherapy alone).6 Vemurafenib (Zelboraf, Genentech) administered in combination with ipilimumab in the treatment of melanoma was responsible for asymptomatic but severe liver toxicity with an early elevation of bilirubin or transaminases within three weeks after ipilimumab treatment was initiated, causing the trial to be stopped.6


Geriatric Patients

It is well known that advanced age is not only a risk factor for cancer, but is also associated with a poor prognosis.6 Half of all malignancies are diagnosed in patients older than 65 years of age.6 ICBs, in particular, represent a new opportunity for improving clinical outcomes in older patients with cancer.6 In fact, anti-CTLA-4 and anti-PD-1/PD-L1 ICB agents have been approved for treatment of elderly patients with advanced melanoma, NSCLC, or RCC.6 However, there are concerns that comorbidities, comedications, age-related immune system impairment (i.e., “immunosenescence”), and reduced functional reserve might affect the efficacy and tolerance of ICBs in elderly patients.6 Older patients also have higher levels of autoantibodies, increasing the concern that ICB treatment may reveal subclinical autoimmune diseases.6

Despite these concerns, data that have been collected for elderly patients in clinical trials of ICBs have been promising; the benefit observed with anti-CTLA-4 and anti-PD-1 agents in these patients is similar to that in the overall population.6 In 2015, a meta-analysis including 3,322 patients from six phase 3, randomized, controlled ICB clinical trials (three with ipilimumab, two with nivolumab, and one with tremelimumab [AstraZeneca]) was conducted.50 ICBs had been studied in the treatment of melanoma in four trials, prostate cancer in one trial, and NSCLC in one trial.50 The cutoff age specified for the subgroup analysis of elderly patients was 65 years in five trials and 70 years in one trial.50 The results of this meta-analysis indicated that a significant difference in OS had occurred in the 2,078 younger patients who had received ICB treatment compared with the control group (hazard ratio [HR], 0.73; 95% confidence interval [CI], 0.66–0.81; P < 0.001).50 The subgroup analysis in this study also showed that ICB treatment had significantly improved OS in 1,244 older patients in comparison with the control group (HR, 0.72; 95% CI, 0.58–0.90; P = 0.004).50 These results demonstrated that there was no statistically significant difference in OS between the subgroups of younger and older patients who had been treated with ICBs based on the pooled OS HRs (P = 0.93).50

In addition, no overall differences in safety have been observed for elderly patients in clinical trials with different FDA-approved ICBs.6 In one trial in which elderly patients with melanoma were treated with ipilimumab, investigators reported that patients older than 70 years of age presented with irAEs at a frequency similar to the overall study population.51 In addition, a retrospective analysis was conducted of irAEs in patients younger than 65 years of age compared to those older than 65 years who had received nivolumab for the treatment of melanoma.52 This study analyzed pooled data for 148 patients who had been treated with nivolumab alone or nivolumab plus peptide vaccine every two weeks for at least 12 weeks.52 The data showed no statistically significant differences in the characteristics, grade, and frequency of irAEs for patients older than 65 years compared with those younger than 65 years.52

Dosage adjustment of ICBs for elderly patients has also been determined to be unnecessary, even in patients with mild or moderate renal impairment (creatinine clearance of at least 30 mL/min) or mild hepatic impairment (total bilirubin greater than the upper limit of normal).6 However, it is important to consider that currently approved ICBs have not been evaluated in patients with severe renal or hepatic impairment.6 Currently approved ICBs are not metabolized by cytochrome P450 enzymes, so drug interactions due to enzymatic competition are not expected.6 However, patients treated with antiaggregants or anticoagulants must be carefully monitored for symptoms of autoimmune thrombocytopenia or colitis (increasing risks for gastrointestinal hemorrhage).6 In addition, because the use of corticosteroids may hypothetically interfere with ICB efficacy, these drugs should be avoided at baseline.6

Although the efficacy and safety of ICBs in elderly patients seem similar to the population at large, most clinical studies to date have enrolled only a small number of elderly patients, so clinical results are confined to subgroup analyses.6 Dedicated studies investigating cancer treatment with ICBs in elderly patients are necessary to confirm these results.6

Clinical Management of ICB Side Effects

The use of ICBs for cancer treatment is likely to expand widely in the near term; it is therefore critical that health care professionals become more familiar with the suggested guidelines for the management of the irAEs that occur with these agents.6 Current recommendations are based solely on expert consensus because prospective studies to evaluate and standardize protocols for the management of irAEs occurring with ICB treatment have not been conducted.6,17 Proposed principles and guidelines are summarized in the following section.

Before Initiating ICB Cancer Immunotherapy

Before initiating ICB treatment, a personal and family history of chronic viral infection or autoimmune disease should be taken because these agents may potentiate these conditions.6,17 Controlled autoimmune disease is not usually considered to be a contraindication for treatment with currently approved ICBs; however, in such cases, these agents should be used with caution only after considering the potential risk–benefit for the individual.6,17 To encourage early identification of irAE symptoms, it is important to inform the patient, family, and his or her caregivers about the characteristics of irAEs.6,17 Patients should be urged to promptly report new symptoms or the worsening of pre-existing symptoms to allow for rapid and proper evaluation.6,17 This is particularly important because early detection and prompt treatment of irAEs could limit their severity.6,17 Patients should also be told that irAEs may occur at any time during treatment or even after discontinuation.6,17

Patients with cancer can present with toxicity sequelae from previous treatments, so laboratory tests, a physical examination, and imaging conducted at baseline should be taken for reference.6,17 Minimal testing for patients should include renal function, serum electrolytes, a complete blood count, liver function tests, and a thyroid evaluation.6,17 Chest imaging should be performed at baseline for reference in case pulmonary toxicity occurs during ICB treatment.6,17 Baseline comorbidities should be properly evaluated both before initiation and during treatment.6,17 During the physical evaluation, the clinician should look in particular for symptoms of gastrointestinal (diarrhea), respiratory (dyspnea, cough), or dermatological (pruritus, rash) issues, as well as nonspecific general signs that may suggest endocrine toxicity, such as thyroid dysfunction.6,17

Monitoring for irAEs in Patients on ICBs

The time to onset and resolution of irAEs occurring with ICBs differs from what is often seen with conventional cancer treatments.6 The majority of irAEs usually occur within the first four months of ICB treatment; however, immune toxicities can occur at any time during therapy, as well as several months after discontinuation.6 Therefore, careful monitoring for irAEs throughout treatment and after termination is warranted.6,17 A suspected or diagnosed irAE should always be closely monitored so that any worsening or relapse is detected.6,17 Although new symptoms or worsening of pre-existing symptoms should be considered and investigated as a possible irAE, these symptoms may also be associated with disease progression or intercurrent infection, which must first be ruled out.6,17 Elderly patients should be monitored carefully, as associated comorbidities can more easily worsen.6,17

Laboratory tests to monitor the patient while on ICB treatment should specifically assess hematologic toxicity (thrombocytopenia, anemia), liver function (transaminase elevation), and renal toxicity (increased serum creatinine).6,17 Thyroid-stimulating hormone should be tested routinely every two to three months.6,17 Because irAEs may occur after treatment is discontinued, it has been proposed that patient clinical and laboratory evaluations should be conducted every three to six months for a year after treatment cessation.6,17

Treating irAEs in Patients on ICBs

Once an irAE is detected, it should be closely monitored so that worsening or relapse is detected promptly; practitioners should also inform patients about self-monitoring.6,17 Most irAEs occurring with ICBs are mild and can be treated symptomatically.3,6 Treatment of irAEs may also require immunosuppressive agents, such as steroids, to target a hyperimmune response.3 However, some symptomatic treatments, such as antihistamines for pruritis or corticosteroids, may expose elderly patients to iatrogenic events, such as mental-status disturbance or worsening diabetes.6,17 It should also be considered that the immunosuppressive activity of corticosteroids may attenuate the antitumor immune system stimulation triggered by ICBs.3 Depending on the severity of the irAEs, close monitoring, interruption, or discontinuation of the ICB, introduction of corticosteroid therapy, and in some cases more immunosuppressive medications such as anti-tumor necrosis factor therapy may be required.6,17 Currently, dose reduction for the FDA-approved ICBs is not recommended.6,17

Resolution of irAEs can be highly variable across different types of toxicities— gastrointestinal, renal, and hepatic toxicities usually improve quickly upon the initiation of immunosuppressant treatment, whereas rash and endocrine-related irAEs tend to be more chronic.6,17 Endocrine insufficiencies may require long-term hormonal substitution.6,17 If required, cortico-steroid treatment should be tapered gradually over a period of more than one month to avoid the recurrence or worsening of the irAE.6,17 Lastly, to avoid life-threatening opportunistic infections, prolonged immunosuppressive treatment should be properly monitored and prophylactic treatment instituted.6,17


The use of cancer immunotherapy agents to stimulate the immune system to recognize and attack malignancies has provided new possibilities for effective cancer treatment.1 The last few decades have seen the development of a range of novel and effective immunotherapies, broadening oncologists’ choice of weapons to fight cancer.5 Many cytokine-based approaches and numerous mAbs have already become the standard of care for treating various malignancies; however, other strategies, including cancer vaccines and cell-based approaches, remain experimental with few exceptions.5 Fortunately, these and other immunotherapy methods are continuing to be investigated in clinical trials and will hopefully provide long-awaited cures for patients with relapsed and refractory malignancies.

Figure and Tables

Representative Immune-Related Adverse Events Observed With Immune Checkpoint Blockers6,12

Examples of Cancer Immunotherapies With Demonstrated Efficacy1,3

Immunotherapy Cancer Type
Cell-based therapy
Allogeneic hematopoietic stem cell transplant AML, hematologic malignancies
Autologous cell transfer MM
Genetically modified T-cell infusions Leukemias, lymphomas
High-dose recombinant interleukin-2 MM, RCC
Monoclonal antibodies
Therapeutic monoclonal antibodies Lymphomas, HER-2+ breast cancer, CRC
Immune checkpoint blockers MM, RCC, NSCLC
Sipuleucel-T Prostate cancer
gp100 Melanoma

AML = acute myeloid leukemia; CRC = colorectal cancer; HER-2+ = human epidermal growth factor receptor 2- positive; MM = metastatic melanoma; NSCLC = non–small-cell lung cancer; RCC = renal cell carcinoma.

Therapeutic and Immune Checkpoint Blocker Monoclonal Antibodies Approved for Cancer Treatment5,10,53

Generic Name (Brand, Manufacturer) FDA Approval Target Structure/Description Indication(s)
Alemtuzumab (Campath, Genzyme) 2001 CD52 Humanized IgG1 B-cell CLL
Atezolizumab* (Tecentriq, Genentech) 2016 PD-L1 Humanized IgG1 Locally advanced or metastatic UC; metastatic NSCLC
Avelumab* (Bavencio, EMD Serono) 2017 PD-L1 Human IgG1 Merkel cell carcinoma; UC
Bevacizumab (Avastin, Genentech) 2004 VEGF Humanized IgG1 Metastatic CRC and RCC; NSCLC; glioblastoma; cervical cancer; epithelial ovarian, fallopian tube, or primary peritoneal cancer
Blinatumomab (Blincyto, Amgen) 2014 CD19/CD3 BiTE B-cell ALL
Brentuximab vedotin (Adcetris, Seattle Genetics) 2011 CD30 Chimeric IgG1 conjugated with mitotic toxin MMAE HL; systemic anaplastic large cell lymphoma
Cetuximab (Erbitux, Eli Lilly) 2004 EGFR Chimeric IgG1 CRC; HNSCC
Daratumumab (Darzalex, Janssen Biotech) 2015 CD38 Humanized IgG1 MM
Durvalumab* (Imfinzi, AstraZeneca) 2017 PD-L1 Human IgG1 UC
Ibritumomab tiuxetan (Zevalin, Spectrum Pharmaceuticals) 2002 CD20 Mouse IgG1 conjugated with radionuclide Y90 B-cell NHL
Ipilimumab* (Yervoy, Bristol-Myers Squibb) 2011 CTLA-4 Human IgG1 Metastatic melanoma
Nivolumab* (Opdivo, Bristol-Myers Squibb) 2014 PD-1 Human IgG4 Metastatic melanoma; metastatic NSCLC; advanced RCC; HL; HNSCC; advanced or metastatic UC
Obinutuzumab (Gazyva, Genentech) 2013 CD20 Glycoengineered IgG1 CLL; follicular lymphoma
Ofatumumab (Arzerra, Novartis) 2009 CD20 Human IgG1 CLL
Olaratumab (Lartruvo, Eli Lilly) 2016 PDGFR-α Human IgG1 Soft tissue sarcoma
Panitumumab (Vectibix, Amgen) 2006 EGFR Human IgG2 Metastatic CRC
Pembrolizumab* (Keytruda, Merck Sharp & Dohme) 2014 PD-1 Humanized IgG4 Metastatic melanoma; NSCLC; metastatic
Pertuzumab (Perjeta, Genentech) 2012 HER-2 Humanized IgG1 Breast cancer
Rituxumab (Rituxan, Genentech) 1997 CD20 Chimeric IgG1 NHL; CLL
Ramucirumab (Cyramza, Eli Lilly) 2014 VEGFR2 Human IgG1 NSCLC; gastric cancer; metastatic CRC
Siltuximab (Sylvant, Janssen Biotech) 2014 IL-6 Chimeric IgG1 Multicentric Castleman’s disease
Trastuzumab (Herceptin, Genentech) 1998 HER-2 Humanized IgG1 Breast cancer; metastatic gastric or gastroesophageal junction adenocarcinoma
Trastuzumab emtansine (Kadcyla, Genentech) 2013 HER-2 Humanized IgG1 Metastatic breast cancer

*Immune checkpoint blocker monoclonal antibodies.

Please see the approved label for complete prescribing information regarding these agents.

ALL = acute lymphocytic leukemia; BiTE = bispecific T-cell engager; CLL = chronic lymphocytic leukemia; CRC = colorectal cancer; CTLA-4 = cytotoxic T-lymphocyte antigen 4; dMMR = mismatch repair-deficient; EGFR = epidermal growth factor receptor; FDA = Food and Drug Administration; HER-2 = human epidermal growth factor receptor 2; HL = Hodgkin’s lymphoma; HNSCC = head and neck squamous cell carcinoma; IL = interleukin; MM = multiple myeloma; MMAE = monomethyl auristatin E; MSI-H = microsatellite instability-high; NHL = non-Hodgkin’s lymphoma; NSCLC = non–small-cell lung cancer; PD-1 = programmed death-1; PDGRF-α = platelet-derived growth factor receptor-alpha; PD-L1 = programmed death ligand-1; RCC = renal cell carcinoma; UC = urothelial carcinoma; VEGF = vascular endothelial growth factor; VEGFR2 = vascular endothelial growth factor receptor 2.


  1. Weiner LM. Cancer immunology for the clinician. Clin Adv Hematol 2015;13;(5):299–306.
  2. Zugazagoitia J, Guedes C, Ponce S, et al. Current challenges in cancer treatment. Clin Ther 2016;38;(7):1551–1566.
  3. Alatrash G, Jakher H, Stafford PD, Mittendorf EA. Cancer immunotherapies, their safety and toxicity. Expert Opin Drug Saf 2013;12;(5):631–645.
  4. Karlitepe A, Ozalp O, Avci O. New approaches for cancer immunotherapy. Tumor Biol 2015;36;(6):4075–4078.
  5. Klener PJrOtahalP, Lateckova L, Klener P. Immunotherapy approaches in cancer treatment. Curr Pharm Biotechnol 2015;16;(9):771–781.
  6. Helissey C, Vicier C, Champiat S. The development of immunotherapy in older adults: new treatments, new toxicities?. J Geriatr Oncol 2016;7;(5):325–333.
  7. Grady D. Harnessing the immune system to fight cancer. The New York Times July30, 2016; Available at: Accessed August 17, 2016
  8. Goel G, Sun W. Cancer immunotherapy in clinical practice—the past, present, future. Chin J Cancer 2014;33;(9):445–457.
  9. Pardoll D. Cancer and the immune system: basic concepts and targets for intervention. Semin Oncol 2015;42;(4):523–538.
  10. Neves H, Kwok HF. Recent advances in the field of cancer immunotherapy. BBA Clin 2015;3:280–288.
  11. Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest 2015;125;(9):3335–3337.
  12. Kottschade L, Brys A, Peikert T, et al. A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy. Melanoma Res 2016;26;(5):469–480.
  13. Smit MA, Jaffee EM, Lutz ER. Cancer immunoprevention—the next frontier. Cancer Prev Research 2014;7;(11):1072–1080.
  14. Catapano A, Papadopoulos N. The safety of therapeutic monoclonal antibodies. Atherosclerosis 2013;228;(1):18–28.
  15. American Cancer Society. Monoclonal antibodies to treat cancer  Available at: Accessed October 26, 2016
  16. National Cancer Institute. Checking in on cancer checkpoint inhibitors  Available at: Accessed October 26, 2016
  17. Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 2016;27;(4):559–574.
  18. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012;12:269–281.
  19. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011;17:4550–4557.
  20. Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011;364:2119–2127.
  21. Creagan ET, Ahmann DL, Frytak S, et al. Phase II trials of recombinant leukocyte A interferon in disseminated malignant melanoma: results in 96 patients. Cancer Treat Rep 1986;70:619–624.
  22. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7–17.
  23. Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005;CD001425
  24. Schuchter LM. Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?. J Clin Oncol 2004;22:7–10.
  25. Klapper JA, Downey SG, Smith FO, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 2008;113:293–301.
  26. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994;271:907–913.
  27. Antony GK, Dudek AZ. Interleukin 2 in cancer therapy. Curr Med Chem 2010;17:3297–3302.
  28. Poust JC, Woolery JE, Green MR. Management of toxicities associated with high-dose interleukin-2 and biochemotherapy. Anticancer Drugs 2013;24:1–13.
  29. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:3127–3132.
  30. Mittendorf EA, Clifton GT, Holmes JP, et al. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 2012;118:2594–2602.
  31. Keilholz U, Letsch A, Busse A, et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009;113:6541–6548.
  32. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411–422.
  33. Berd D, Sato T, Cohn H, et al. Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases. Int J Cancer 2001;94:531–539.
  34. Borrello IM, Levitsky HI, Stock W, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). Blood 2009;114:1736–1745.
  35. Wong KK, Li WA, Mooney DJ, Dranoff G. Advances in therapeutic cancer vaccines. Adv Immunol 2016;130:191–249.
  36. Imlygic (talimogene laherparepvec) prescribing information Thousand Oaks, California: Amgen. 2015;
  37. Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994;86:1159–1166.
  38. Rosenberg SA, Aebersold P, Cornetta K, et al. Gene transfer into humans—immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990;323:570–578.
  39. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850–854.
  40. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008;26:5233–5239.
  41. Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 2016;127;(26):3321–3330.
  42. Suciu S, Mandelli F, de Witte T, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 2003;102:1232–1240.
  43. Cornelissen JJ, van Putten WL, Verdonck LF, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?. Blood 2007;109:3658–3666.
  44. Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009;301:2349–2361.
  45. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945–956.
  46. Khera N, Storer B, Flowers ME, et al. Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation. J Clin Oncol 2012;30:71–77.
  47. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990;76:1464–1472.
  48. Jacobsohn DA, Kurland BF, Pidala J, et al. Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. Blood 2012;120:2545–2552.
  49. Maffini E, Giaccone L, Festuccia M, et al. Ruxolitinib in steroid refractory graft vs. host disease. J Hematol Oncol 2016;9;(1):67
  50. Tomohiro F, Hyman M, Stergios M. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a meta-analysis of randomized controlled trials. Presentation at CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science Into SurvivalNew York, New YorkSeptember 16–19, 2015 Abstract published in Cancer Immunol Res 2016;4(suppl 1):A159
  51. Chiarion-Sileni V, Pigozzo J, Ascierto PA, et al. Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centers through the expanded access program. J Exp Clin Cancer Res 2014;33;(1):30
  52. Freeman M, Weber J. Subset analysis of the safety and efficacy of nivolumab in elderly patients with metastatic melanoma. J Immunother Cancer 2015;3;(suppl 2):P133
  53. Drugs@FDA. FDA approved drug products  Available at: Accessed June 5, 2017